Revue: | Belize journal of medicine |
Base de datos: | PERIÓDICA |
Número de sistema: | 000418449 |
ISSN: | 2225-8116 |
Autores: | Agüero, María Susana1 |
Instituciones: | 1Hospital Ramón Sarda, Buenos Aires. Argentina |
Año: | 2012 |
Periodo: | Feb |
Volumen: | 1 |
Número: | 2 |
Paginación: | 5-9 |
País: | Belice |
Idioma: | Inglés |
Tipo de documento: | Artículo |
Enfoque: | Analítico |
Resumen en inglés | Fetal nuchal translucency thickness (NT) at 11–13+6 weeks scan has been combined with maternal age to provide an effective method of screening for trisomy 21; for an invasive testing rate of 5%, about 75% of trisomic pregnancies can be identified. When maternal serum free ß-human chorionic gonadotropin (ß-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11–13+6 weeks are also taken into account, the detection rate of chromosomal defects is about 85–90%.It was found that in 60–70% of fetuses with trisomy 21, the nasal bone is not visible in the 11–13+6 weeks scan and examination of the nasal bone can increase screening detection rate by the first trimester scan and serum biochemistry to more than 95%. In addition to its role in the assessment of risk for trisomy 21, increased nuchal translucency thickness can also identify a high proportion of other chromosomal defects and is associated with major abnormalities of the heart and great arteries, and a wide range of genetic syndromes |
Disciplinas: | Medicina |
Palabras clave: | Ginecología y obstetricia, Diagnóstico, Genética, Ultrasonido, Tamizaje, Anomalías cromosómicas, Translucidez, Trisomía 21, Gonadotropina coriónica humana (hCG), Amniocentesis |
Keyword: | Gynecology and obstetrics, Diagnosis, Genetics, Ultrasound, Screening, Chromosomal abnormalities, Translucency, Trisomy 21, Human chorionic gonadotropin (hCG), Amniocentesis |
Texte intégral: | Texto completo (Ver PDF) |